当前位置: X-MOL 学术Mol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CRISPR-derived genome editing therapies: Progress from bench to bedside
Molecular Therapy ( IF 12.1 ) Pub Date : 2021-10-05 , DOI: 10.1016/j.ymthe.2021.09.027
Holly A Rees 1 , Alex C Minella 1 , Cameron A Burnett 2 , Alexis C Komor 2 , Nicole M Gaudelli 1
Affiliation  

The development of CRISPR-derived genome editing technologies has enabled the precise manipulation of DNA sequences within the human genome. In this review, we discuss the initial development and cellular mechanism of action of CRISPR nucleases and DNA base editors. We then describe factors that must be taken into consideration when developing these tools into therapeutic agents, including the potential for unintended and off-target edits when using these genome editing tools, and methods to characterize these types of edits. We finish by considering specific challenges associated with bringing a CRISPR-based therapy to the clinic, including manufacturing, regulatory oversight, and considerations for clinical trials that involve genome editing agents.

中文翻译:


CRISPR 衍生的基因组编辑疗法:从实验室到临床的进展



CRISPR 衍生的基因组编辑技术的发展使得人类基因组内 DNA 序列的精确操作成为可能。在这篇综述中,我们讨论了 CRISPR 核酸酶和 DNA 碱基编辑器的初步发展和细胞作用机制。然后,我们描述了将这些工具开发成治疗剂时必须考虑的因素,包括使用这些基因组编辑工具时发生意外和脱靶编辑的可能性,以及表征这些类型编辑的方法。最后,我们考虑了将基于 CRISPR 的疗法引入临床相关的具体挑战,包括制造、监管以及涉及基因组编辑剂的临床试验的考虑因素。
更新日期:2021-10-05
down
wechat
bug